Search

everythinglearnresearchcommunity

for

Search:↓

The conversation discusses using hair follicle dermal papilla exosomes for hair loss treatment. It inquires about purchasing options for this treatment.

PP405 shows promising results for hair density improvement, potentially outperforming Minoxidil in a shorter time. However, its public release is expected around 2029/2030, and its cost and availability remain uncertain.

Hydrocortisone helps relieve scalp itchiness, possibly caused by minoxidil. Users discuss its effectiveness for managing this side effect.

A user discusses using a hemp inflammation cream for hair loss, noting it contains aloe vera, hemp extract, rosemary oil, glycerin, emu oil, menthol, and MSM, which are beneficial for hair loss. They consider using the cream instead of making their own topical treatment.

Hair loss discussion includes stemoxydine treatment. Users share experiences and effects on hair and scalp.

Replicel's results were delayed, but Shiseido might share data at BioJapan on October 11. Users are hopeful for new treatments like RCH-01, potentially eliminating the need for finasteride or minoxidil.

Pelage is delaying the start of phase 3 trials for PP405 to 2026 due to necessary regulatory processes, despite having $120 million in funding. Users discuss the potential of PP405 for hair regrowth, with some expressing skepticism and others hopeful for new treatments like Breezula.

The post and conversation are about using bimatoprost for hair regrowth, with the user seeking a higher concentration to enhance results. The user also discusses difficulties in sourcing the powder for personal use.

The conversation discusses DIY cosmetic procedures like PRP, mesotherapy, and micro-needling, with some users experimenting with Minoxidil, finasteride, and RU58841 for hair loss. It highlights a community of mostly older women performing these treatments themselves.

The user switched from liquid to foam minoxidil to reduce skin irritation but finds foam harder to apply effectively to the scalp. A suggestion was made to melt the foam into a liquid for easier application.

Mixing topical solutions like Morr F 10% (Minoxidil) and L'Oreal Seryoxyl (Stemoxydine) before application may not reduce their effectiveness. The goal is to apply treatments all at once instead of multiple times a day.

User asks about Eucapil (fluridil) for hair loss, its effectiveness, safety, and where to buy in Australia. Others share experiences and purchase options.

ET-02 (RS 5441) shows promising results for hair growth, performing better in humans than in mice. There is debate over the effectiveness compared to minoxidil, with some users wanting more detailed data.

The conversation is about the interest in testing verteporfin, potentially with a dermaroller, for hair loss treatment. There is frustration over the lack of group buys for promising treatments compared to past efforts with less evidence.

The conversation is about someone considering adding topical Cetirizine 1% to their existing hair loss treatment regimen and seeking advice on where to buy it and others' experiences with it.

User discusses potential hair loss treatment SCUBE3 and shares mixed opinions on its effectiveness. One user reports positive results after applying SCUBE3 following microneedling.

RU58841 is being mixed with Minoxidil solution, but concerns arise about water causing instability. Mixing with water may lead to hydrolysis, potentially reducing effectiveness.

Hair loss discussion includes treatments like Minoxidil, Finasteride, and RU58841. Eucapil (fluridil) is approved as a cosmetic hair-care agent in Europe, but users question the level of testing required for approval.

The conversation is about finding a trustworthy and affordable source for RU58841 in Europe, with a comparison between Anagenic and Actifolic. The user seeks experiences from others in the EU to avoid receiving water instead of the product.

The conversation discusses concerns about using hair fibers while microneedling, specifically the potential for clogging pores. It is suggested that microneedling should not cause bleeding.

KX-826 Phase II results show that a 0.5% concentration performs better than 1% for treating male pattern baldness. Concerns about receptor upregulation from long-term DHT antagonism were mentioned.

A user is considering ordering topical finasteride with castor and rosemary oil from a Turkish pharmacy. They are debating whether to include the oils or use only PG and ethanol as the carrier.

User tried cheap hair fibers from Amazon, significantly improved appearance of thinning hair. Fixing spray recommended to prevent fibers from blowing off.

The conversation questions the lack of feedback on the effectiveness of PGE2 and setipiprant for hair loss, despite their availability. The user is puzzled by the absence of reviews or results, whether positive or negative.

Autologous exosome treatment for hair loss is being discussed as an emerging option. Minoxidil, finasteride, and RU58841 are also mentioned as treatments.

The user started using topical minoxidil, oral finasteride, GHK-CU, and HGH in October, resulting in thicker hair and improved overall health. They experienced minor side effects like dehydration from HGH but reported benefits like clearer skin, better recovery, and muscle gain.

Exosome Therapy for hair loss, including its results and cost. The discussion also touches on the various serums used in this therapy.

HairClone is developing cell replacement treatments to rejuvenate and generate hair follicles, and has launched a crowdfunding campaign. A user expressed skepticism about the need for crowdfunding.

The conversation discusses using topical synthetic prostaglandins like Bimatoprost, Latanoprost, and cetirizine for hair growth. The user shares a link suggesting these treatments may be effective.

The solution contains minoxidil, finasteride, azelaic acid, caffeine, retinoic acid, and procapil. Users suggest minoxidil with tretinoin and a 5-alpha reductase inhibitor, while dismissing retinoic and azelaic acids as unnecessary.